Algeta

Alpha-emitter anticancer agents

Algeta developed Xofigo® (radium-223 dichloride), a first-in-class, targeted alpha-pharmaceutical that was approved by the US FDA and European EMA for treatment of patients with symptomatic bone metastases secondary to castration-resistant prostate cancer.

CEO  Andrew Kay

Advent Contact  Shahzad Malik

Advent invested in the Series A in 2005. Algeta listed on the Oslo Stock exchange in March 2007 and was acquired by Bayer in 2014 for $2.9B.
Exited Investments
20 January 2014 in Algeta, Press Release

Bayer commences voluntary cash offer to acquire the entire issued share capital of Algeta

Press Release.   Oslo, Norway, 20 January, 2014 - Algeta ASA ("Algeta"; OSE: ALGETA) today announced that Aviator Acquisition AS, a wholly-owned subsidiary of Bayer Nordic SE, has commenced the…
Read More
19 December 2013 in Algeta, Press Release

The Board of Directors of Algeta ASA unanimously recommends voluntary cash offer from Bayer to acquire the entire issued share capital of Algeta

Press Release.   Not intended for US media Offer at NOK 362 per Algeta share, in cash, valuing the total share capital of Algeta at approximately NOK 17.6 billion (USD…
Read More
15 May 2013 in Algeta, Press Release

Algeta announces that Xofigo® (radium-223 dichloride) has been approved by the US FDA

Press Release.   New treatment for castration-resistant prostate cancer (CRPC) patients with bone metastases Xofigo shown in a pivotal phase III trial to significantly improve overall survival Algeta to host…
Read More
14 December 2012 in Algeta, Press Release

Algeta’s partner Bayer submits New Drug Application to US FDA for Radium-223 Dichloride

Press Release.   Oslo, Norway, 14 December 2012 - Algeta ASA (OSE: ALGETA) announces that Bayer has submitted a New Drug Application (NDA) to the US Food and Drug Administration…
Read More
12 December 2012 in Algeta, Press Release

Algeta’s partner Bayer submits Radium-223 Dichloride for EU Marketing Authorisation

Press Release.   Oslo, Norway, 12 December 2012 - Algeta ASA (OSE: ALGETA) announces that Bayer has submitted a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for…
Read More
6 June 2011 in Algeta, Press Release

Positive Outcome for Algeta in Pivotal Alpharadin Study

Press Release.   Positive Outcome of Interim Analysis of pivotal Alpharadin study: Primary endpoint met in Phase III ALSYMPCA study. Alpharadin is in development for treating bone metastases in patients…
Read More
4 November 2010 in Algeta, Press Release

Algeta wins Scrip Award for Biotechnology Company of the Year

Press Release.   Scrip's Biotech Company of the Year award seeks to acknowledge the vital importance to the industry of biotechnology’s cutting-edge science and entrepreneurial spirit. This year, from a…
Read More
3 August 2010 in Algeta, Press Release

Algeta concludes agreements for the manufacture and supply of Alpharadin for future commercial sale

Press Release.   Oslo, Norway - Algeta ASA (OSE: ALGETA), the focused oncology company, today has announced it has concluded two agreements for the manufacture and supply of Alpharadin for…
Read More
12 October 2009 in Algeta, Press Release

New phase II data presented at ECCO 15 and 34th ESMO Congress reinforces exciting potential of Algeta’s Alpharadin as a new treatment for bone metastases in cancer patients

Press Release. Oslo, Norway, 22 September 2009 - Algeta ASA (OSE:ALGETA), the cancer therapeutics company, announces that new clinical data from three phase II clinical trials with Alpharadin have been…
Read More
1 July 2009 in Algeta, Press Release

Algeta – Magic Bullet is my Weapon

Press Release.   http://www.dailyexpress.co.uk/posts/view/110873/Magic-bullet-is-my-weapon
Read More
28 August 2008 in Algeta, Press Release

Algeta Reports Positive Headline Phase II Data on Pain Palliation with Alpharadin

Press Release.   Oslo, Norway, 28 August 2008 - Algeta ASA (OSE: ALGETA), the Norwegian cancer therapeutics company, today announced that the primary objective of its BC1-03 Phase II pain…
Read More
21 February 2008 in Algeta, Press Release

Algeta receives IND Approval for Alpharadin(TM) to commence Clinical Development in the USA

Press Release.   Oslo, Norway, 21 February 2008 - Algeta ASA (OSE: ALGETA), the cancer therapeutics company, today announced that it will shortly commence clinical development of Alpharadin(TM) in HRPC…
Read More
20 December 2007 in Algeta, Press Release

Algeta provides update on its late-stage clinical programme for Alpharadin in prostate cancer

Press Release.   Oslo, Norway, 20 December 2007 - Algeta ASA (OSE: ALGETA), the cancer therapeutics company, is pleased to provide an update on its clinical development of Alpharadin in…
Read More
25 September 2007 in Algeta, Press Release

Alpharadin treatment more than doubles survival rate in prostate cancer patients

Press Release.   Algeta presents new Phase II clinical trial data at ECCO   Oslo, Norway, 25 September 2007 - Algeta ASA (OSE: ALGETA), the Norwegian cancer therapeutics company, today…
Read More
4 June 2007 in Algeta, Press Release

Algeta’s Phase II Clinical Study Data for Alpharadin™ in Prostate Cancer Published in Lancet Oncology

Press Release.   Oslo, Norway, 4 June 2007 - Algeta ASA (OSE: ALGETA), the Norwegian cancer therapeutics company, is pleased to announce that clinical Phase II study data for Alpharadin™…
Read More
26 March 2007 in Algeta, Press Release

Advent Venture Partners’ portfolio company Algeta raises NOK 250 million in successful offering

Press Release.   Oslo, Norway, 26 March 2007 – Algeta ASA, the Norwegian cancer therapeutics company, today announced the successful closing of its initial public offering. The offering was more…
Read More
1 February 2007 in Algeta, Press Release

Advent Ventures Portfolio Company Algeta Applies for Listing on the Oslo Stock Exchange

Press Release.   Oslo, Norway, February 1st, 2007 - Algeta ASA, the Norwegian therapeutics company, today announced its application for listing on the Oslo Stock Exchange (Oslo Børs). Algeta is…
Read More